Rallybio Corporation (RLYB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Rallybio Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Rallybio Corporation (RLYB) has returned 63.42% so far this year and 71.31% over the past 12 months.

Based on dividend-adjusted daily data since Jul 29, 2021, RLYB's average daily return is +0.01%, while the average monthly return is -0.46%.

Historically, 49% of months were positive and 51% were negative. The best month was Feb 2024 with a return of +72.2%, while the worst month was Nov 2023 at -54.5%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.

On a daily basis, RLYB closed higher 48% of trading days. The best single day was Apr 11, 2024 with a return of +82.8%, while the worst single day was Apr 8, 2025 at -41.2%.

Rallybio Corporation has an annualized alpha of -9.00%, beta of 1.19, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since July 30, 2021.

• This stock participated in 35.50% of S&P 500 Index downside but only -98.56% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RLYB ranks 67 for risk / return — better than 67% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Rallybio Corporation (RLYB) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Rallybio Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Rallybio Corporation was 98.93%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Rallybio Corporation drawdown is 95.21%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Rallybio Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Rallybio Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.